Drug intelligence / Profile preview

Biocity Biopharmaceutics bispecific antibody (undisclosed)

Development stage: Preclinical
Lead developer: Biocity Biopharmaceutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Biocity Biopharmaceutics bispecific antibody (undisclosed) is a preclinical-stage therapeutic candidate being developed for the treatment of solid tumors. As a bispecific antibody, the molecule is engineered to simultaneously bind to two distinct antigens or epitopes, a strategy often employed to enhance tumor selectivity, bridge immune cells to cancer cells, or dual-block signaling pathways. Specific details regarding its molecular targets, internal code name, and precise mechanism of action have not yet been publicly disclosed by the developer.

Other names: Undisclosed bispecific antibody

Targets

CD47 (Cluster of Differentiation 47)CD24 (Cluster of Differentiation 24)

Beyond the preview

Go deeper on Biocity Biopharmaceutics bispecific antibody (undisclosed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocity Biopharmaceutics bispecific antibody (undisclosed).

Explore the full profile